**EXPLANATORY STATEMENT**

**INSTRUMENT NUMBER PB 146 OF 2024**

***NATIONAL HEALTH ACT 1953***

***National Health (Weighted average disclosed price – April 2025 reduction day) Determination 2024***

**Authority**

This legislative instrument (Instrument) is made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the *National Health Act 1953* (the Act), and makes certain determinations relating to price disclosure for brands of pharmaceutical items with a data collection period ending 30 September 2024 (2025 April Cycle).

This Instrument repeals the previous determination made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the Act for the 2024 October Cycle (PB 67 of 2024) pursuant to subsection 33(3) of the *Acts Interpretation Act 1901*.

**Purpose**

This Instrument determines a ‘weighted average disclosed price’ (WADP) for listed brands of pharmaceutical items in the 2025 April Cycle under subsection 99ADB(4) of the Act.

This Instrument also determines a reduction day of 1 April 2025 for listed brands in the 2025 April Cycle with a data collection period ending on 30 September 2024.

A provision-by-provision description of the Instrument is contained in the Attachment.

**Background**

Part VII of the Act is the legislative basis for the Pharmaceutical Benefits Scheme (PBS) by which the Commonwealth provides reliable, timely, and affordable access to a wide range of medicines for Australians.

Part VII, Division 3B of the Act deals with price disclosure. Price disclosure provides for the ‘approved ex-manufacturer price’ of a ‘brand of a pharmaceutical item’ to be reduced on a reduction day in certain specified circumstances. The reduction is based on sales revenue, incentives and volume data collected from responsible persons (drug companies) and occurs in accordance with the Act and the *National Health (Pharmaceutical Benefits) Regulations 2017* (the Regulations).

A responsible person for a listed brand in Schedule 1 of this instrument, where the ‘approved ex-manufacturer price’ for the listed brand on 1 April 2025 will be more than the ‘adjusted approved ex-manufacturer price’, will receive a price reduction for the listed brand on and from 1 April 2025: subsections 99ADH(3) and (4).

*Subsection 99ADB(4) – ‘weighted average disclosed price’*

Subsection 99ADB(4) of the Act provides that the Minister may, by legislative instrument, determine the WADP of a listed brand in accordance with the Regulations.

Subsection 99ADB(6) of the Act provides that without limiting subsection 99ADB(4), the Regulations may prescribe a method for determining the WADP for a listed brand. The method may take into account information (if any) that has been provided in compliance with the price disclosure requirements, and any other information, about the listed brand, other listed or delisted brands of the same pharmaceutical item, and all listed or delisted brands of all pharmaceutical items that have the same drug and manner of administration as the pharmaceutical item.

Part 7, Division 2, Subdivision B of the Regulations provides the method for determining a WADP for a listed brand of pharmaceutical item for a ‘data collection period’. ‘Data collection period' is defined in section 67 of the Regulations.

The Act and Regulations provide for brands that are part of the 2025 April Cycle. A brand is in the 2025 April Cycle if:

* the listed brand had a data collection period of six months or more on 30 September 2024; and
* a new brand is listed on the PBS for less than six months, during the data collection period, but is listed for a pharmaceutical item that is subject to price disclosure.

A brand of an exempt item (section 84AH of the Act) is excluded from price disclosure and so does not have data collected or a determination for a reduction day in accordance with section 99ADA of the Act. The current instrument of exempt items is the *National Health (Pharmaceutical Benefits Scheme‑Exempt items ‑ Section 84AH) Determination 2017* (PB 81 of 2017).

The price for new brands of existing pharmaceutical items listed on the PBS after 30 September 2024 will be reduced as a flow-on reduction under section 99ADHA on 1 April 2025 if at least one existing brand of the same pharmaceutical item is in Schedule 1. No WADP or reduction day is determined for these listed brands.

*Paragraph 99ADH(1)(c) – unadjusted price reduction for listed brand or no price reduction for listed brand on reduction day*

Paragraph 99ADH(1)(c) of the Act (read together with subsection 99ADH(3)) provides that a price reduction for a listed brand will not occur unless the ‘unadjusted price reduction’ for a listed brand is at least the applicable percentage threshold set out in the Act. This Instrument reflects unadjusted price reductions that have been calculated in accordance with new paragraph 99ADH(1)(c) from the *National Health Amendment (Enhancing the Pharmaceutical Benefits Scheme) Act 2021,* which provides the following applicable percentage thresholds (effective 1 July 2022):

1. if the brand of the pharmaceutical item is not subject to floor pricing protection—at least 10%; or
2. if the brand of the pharmaceutical item is subject to floor pricing protection and the approved ex manufacturer price of the brand of the pharmaceutical item is more than $4—at least 30%; or
3. if the brand of the pharmaceutical item is subject to floor pricing protection, the approved ex‑manufacturer price of the brand of the pharmaceutical item is more than $4, and the brand of the pharmaceutical item has passed the 12.5% average unadjusted price reduction test set out in subsection 99ADHC (6) of this section—at least 10%.

The ‘unadjusted price reduction’ for a listed brand is defined in subsection 99ADB(1). A brand of a pharmaceutical item which is a designated brand in accordance with the criteria set out in section 99ADHC may have an applicable percentage threshold of 10% (subject to the 12.5% average unadjusted price reduction test at subsection 99ADB(6)) or 30%. For a listed brand of a pharmaceutical item which is not a designated brand, the applicable percentage threshold is 10%.

Listed brands where the unadjusted price reduction is calculated to be at least the applicable percentage threshold appear in Schedule 1 of this Instrument. Listed brands where the respective unadjusted price reduction is calculated as less than the applicable percentage thresholds appear in Schedule 2 of this Instrument. Listed brands in Schedule 2 only have a determined WADP and will not have a price disclosure price reduction on 1 April 2025.

*Subsection 99ADB(4) – determining an ‘adjusted approved ex-manufacturer price’ for a listed brand in Schedule 1*

Subsection 99ADB(7) provides that a subsection 99ADB(4) determination for a listed brand may include the ‘adjusted approved ex-manufacturer price’ for the listed brand.

In this Instrument, where a WADP is determined for listed brands in Schedule 1, the ‘adjusted approved ex-manufacturer price’ is equal to the amount of the WADP. Since listed brands in Schedule 2 will not have a reduction on 1 April 2025, the ‘adjusted approved ex-manufacturer price’ is not included in Schedule 2.

*Paragraph 99ADH(1)(aa) – determining a reduction day*

A price disclosure reduction day must be 1 April, 1 October, or another day prescribed under subsection 99ADH(2) of the Act. Section 66 of the Regulations provides that 1 August and 1 December are prescribed days.

In order for a price reduction to occur for a listed brand, one of the reduction days in the Act or prescribed in the Regulations must be determined for the listed brand under paragraph 99ADH(1)(aa) of the Act, or, the reduction must flow-on to the listed brand to match the reduction on the same date for another listed brand with the same pharmaceutical item, due to section 99ADHA of the Act.

This Instrument determines 1 April 2025 as the reduction day for the relevant brands in Schedule 1 for the 2025 April Cycle.

**Repeal**

This Instrument repeals the previous determination made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the Act for the 2024 October Cycle (PB 67 of 2024) because listed brands in this cycle have had their reduction from this cycle.

**Reliance on subsection 33(3) of the *Acts Interpretation Act 1901***

Under subsection 33(3) of the *Acts Interpretation Act 1901*, where an Act confers a power to make, grant or issue any instrument of a legislative or administrative character (including rules, regulations or by-laws), the power shall be construed as including a power exercisable in the like manner and subject to the like conditions (if any) to repeal, rescind, revoke, amend, or vary any such instrument.

**Consultation**

This Instrument affects certain pharmaceutical companies with medicines listed on the PBS. Pharmaceutical companies with a brand subject to the price disclosure requirements for the 2025 April Cycle disclosed information relevant to this determination directly to Australian Healthcare Associates Pty Ltd, known as the Price Disclosure Data Administrator (PDDA). The PDDA is prescribed in subsection 85(6) of the Regulations as the person to whom, in accordance with paragraph 99ADC(1)(a), a responsible person is to provide price disclosure information. The PDDA provided responsible persons with an opportunity to check that the information disclosed to the PDDA was translated correctly to PDDA data files. This was done prior to that data being used to apply the method set out in the Regulations to arrive at the WADP for listed brands.

Further consultation on this instrument than that set out above, was not considered necessary because affected pharmaceutical companies are provided with an opportunity to dispute any of the outcomes in the determination, through an industry agreed dispute resolution process. Any disputes are resolved through this mechanism prior to the reduction day, which may necessitate further amendments to this instrument.

**Commencement**

This Instrument commences the day after registration.

This Instrument is a legislative instrument for the purposes of the *Legislation Act 2003.*

**ATTACHMENT**

**Details of the *National Health (Weighted average disclosed price – April 2025reduction day) Determination 2024 (PB 146 of 2024)***

**Section 1 Name**

This section provides the name of this instrument is the *National Health (Weighted average disclosed price – April 2025 reduction day) Determination 2024*.

This instrument may also be cited as PB 146 of 2024.

**Section 2 Commencement**

This section provides that this instrument is to commence the day after registration.

**Section 3 Repeal**

This instrument repeals the previous determination made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the Act for the 2024 October Cycle (PB 67 of 2024).

**Section 4 Authority**

This section provides that this instrument is made under the authority of subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the Act.

**Section 5 Definitions**

This section defines certain terms used in the Instrument.

**Part 1 Brands of pharmaceutical items with a weighted average disclosed**

**price; adjusted approved ex-manufacturer price and reduction day**

**Section 6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1**

Under paragraph 99ADH(1)(c) of the Act, listed brands where the unadjusted price reduction is calculated to be at least applicable percentage, appear in Schedule 1 of this instrument. For listed brands that are designated brands in accordance with section 99ADHC of the Act, the applicable percentage is 10% (if the 12.5% average unadjusted price reduction test is passed under subsection 99ADB(6)) or 30%, for all other brands that are not designated brands the applicable percentage is 10%. Brands listed in Schedule 1 are determined for a reduction on the reduction day.

Listed brands where the respective unadjusted price reduction is calculated as less than the applicable percentage, appear in Schedule 2 to this instrument. Brands listed in Schedule 2 are not determined for a reduction on the reduction day.

**Section 7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items**

Subsection 99ADB(7) of the Act provides that a determination of the weighted average disclosed price of a brand of a pharmaceutical item made under subsection 99ADB(4), may include the adjusted approved ex-manufacturer price of the brand of the pharmaceutical item.

This section determines that for a brand of pharmaceutical item specified in column 2 in Schedule 1, the weighted average disclosed price in column 3 is the price that will take effect on the reduction day.

**Section 8 Reduction Day**

This instrument determines 1 April 2025 as the reduction day for the relevant brands (listed in Schedule 1) for the 2025 April Cycle under paragraph 99ADH(1)(aa) the Act.

**Part 2 - Brands of pharmaceutical items with a weighted average disclosed price**

**Section 9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2**

As the unadjusted price reduction is calculated as less than the applicable percentage under paragraph 99ADH(1)(c) for a brand of pharmaceutical item specified in column 2 in Schedule 2, the weighted average disclosed price in column 3 is not the price that will take effect on the reduction day.

**Statement of Compatibility with Human Rights**

*Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011*

***National Health (Weighted average disclosed price – April 2025 reduction day) Determination 2024***

This Legislative Instrument (Instrument) is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

**Overview of the Legislative Instrument**

This Instrument is made pursuant to Part VII, Division 3B of *National Health Act 1953* (the Act) which relates to Price Disclosure.

Price disclosure provides for the ‘approved ex-manufacturer price’ of a ‘brand of a pharmaceutical item’ to be reduced on a reduction day in certain specified circumstances. The reduction is based on sales revenue, incentives and volume data collected from responsible persons (drug companies) and occurs in accordance with the Act and the *National Health (Pharmaceutical Benefits) Regulations 2017*.

This Instrument determines a ‘weighted average disclosed price’ for listed brands under subsection 99ADB(4) of the Act and also determines a reduction day of 1 April 2025 for listed brands in the 2025 April Cycle which are mentioned in Schedule 1 of this instrument.

A responsible person for a listed brand in Schedule 1 of this instrument, provided that the ‘approved ex-manufacturer price’ for the listed brand on 1 April 2025 is more than the ‘adjusted approved ex-manufacturer price’, will receive a price reduction for the listed brand on and from 1 April 2025: subsections 99ADH(3) and (4) of the Act.

**Human rights implications**

This Instrument engages Article 12 of the International Covenant on Economic, Social and Cultural Rights by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

The PBS is a benefit scheme that assists providing subsidised access to medicines for people. This is a positive and supportive step towards attaining the highest standard of health for all Australians. The price disclosure program progressively reduces the price of some PBS medicines, which are subject to competition, ensuring better value for money from these medicines. These reductions may also result in patients accessing these medicines at lower prices.

**Conclusion**

This Instrument is compatible with human rights because it advances the protection of human rights.

**Duncan McIntyre**

**First Assistant Secretary
Technology Assessment and Access Division
Department of Health and Aged Care**